• Johnson & Johnson EVP Jennifer Taubert will retire as worldwide chairman of Innovative Medicine following a 21-year tenure.
• Tom Cavanaugh will succeed Taubert as EVP, worldwide chairman of Innovative Medicine effective Sept. 1, 2026.
• Cavanaugh currently serves as company group chairman, North America, Innovative Medicine.
• He joined the company in 2017, holding senior leadership roles in oncology, immunology, global commercial strategy.
• Before joining, he spent nearly 15 years at Celgene across product development, medical affairs, marketing, regional management in Spain, the U.S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 202608040845BIZWIRE_USPR_____20260804_BW327747) on August 04, 2026, and is solely responsible for the information contained therein.